206 related articles for article (PubMed ID: 15139986)
21. Starting highly active antiretroviral therapy: why, when and response to HAART.
Mocroft A; Lundgren JD
J Antimicrob Chemother; 2004 Jul; 54(1):10-3. PubMed ID: 15163656
[TBL] [Abstract][Full Text] [Related]
22. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
[TBL] [Abstract][Full Text] [Related]
23. [Classification of plastic penile induration (Peyronie's disease)].
Alth G
Wien Klin Wochenschr; 1984 Dec; 96(23):854-7. PubMed ID: 6528613
[TBL] [Abstract][Full Text] [Related]
24. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient.
De Rosa FG; Audagnotto S; Bargiacchi O; Garazzino S; Aguilar Marucco D; Veronese L; Canta F; Bonora S; Sinicco A; Di Perri G
J Infect; 2006 Nov; 53(5):e215-8. PubMed ID: 16549201
[TBL] [Abstract][Full Text] [Related]
25. HIV infection in older patients in the HAART era.
Grabar S; Weiss L; Costagliola D
J Antimicrob Chemother; 2006 Jan; 57(1):4-7. PubMed ID: 16284223
[TBL] [Abstract][Full Text] [Related]
26. Primary HIV-1 infection: to treat or not to treat?
Blankson JN
AIDS Read; 2005 May; 15(5):245-6, 249-51. PubMed ID: 15900634
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of Peyronie's disease (induratio plastica penis) with dimethyl sulfoxide].
Jeromin L; Olszewska Z
Pol Tyg Lek; 1977 Nov; 32(46):1795-6. PubMed ID: 593950
[No Abstract] [Full Text] [Related]
28. Emergence of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for human immunodeficiency virus infection.
Diri E; Lipsky PE; Berggren RE
J Rheumatol; 2000 Nov; 27(11):2711-4. PubMed ID: 11093459
[TBL] [Abstract][Full Text] [Related]
29. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
30. Concurrent granulomatous Pneumocystis carinii and Mycobacterium xenopi pneumonia: an unusual manifestation of HIV immune reconstitution disease.
Chen F; Sethi G; Goldin R; Wright AR; Lacey CJ
Thorax; 2004 Nov; 59(11):997-9. PubMed ID: 15516479
[TBL] [Abstract][Full Text] [Related]
31. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
32. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
[TBL] [Abstract][Full Text] [Related]
33. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Collazos J; Asensi V; Cartón JA
AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
[TBL] [Abstract][Full Text] [Related]
34. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
35. Immunologic findings in Peyronie's disease: a controlled study.
Schiavino D; Sasso F; Nucera E; Alcini E; Gulino G; Milani A; Patriarca G
Urology; 1997 Nov; 50(5):764-8. PubMed ID: 9372889
[TBL] [Abstract][Full Text] [Related]
36. Highly active antiretroviral therapy per se decreased mortality and morbidity of advanced human immunodeficiency virus disease in Hong Kong.
Chan CW; Cheng LS; Chan WK; Wong KH
Chin Med J (Engl); 2005 Aug; 118(16):1338-45. PubMed ID: 16157027
[TBL] [Abstract][Full Text] [Related]
37. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour.
Smit C; Lindenburg K; Geskus RB; Brinkman K; Coutinho RA; Prins M
Addiction; 2006 Mar; 101(3):433-40. PubMed ID: 16499516
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
Kong HH; Myers SA
Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
[TBL] [Abstract][Full Text] [Related]
39. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART).
Authier FJ; Chariot P; Gherardi RK
Muscle Nerve; 2005 Sep; 32(3):247-60. PubMed ID: 15902690
[TBL] [Abstract][Full Text] [Related]
40. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.
Tincati C; Biasin M; Bandera A; Violin M; Marchetti G; Piacentini L; Vago GL; Balotta C; Moroni M; Franzetti F; Clerici M; Gori A
Antivir Ther; 2009; 14(3):321-30. PubMed ID: 19474466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
